Alfred Chung, MD
Hematology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 5
- Since medical school
- 12 years
- Northwestern University Feinberg Medical School, 2014
Offices
5 locations · UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chung’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A137526 · Current
Licensed to practise in California · since 2015 · expires 2026-11-30 · Northwestern University Feinberg School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$577,575
Medicare paid this office $577,575 for 240 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 143 | $43,327 | $122 |
| Return visit (30+ min) | 58 | $6,249 | $77 |
| New patient visit (60+ min) | 33 | $4,796 | $145 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 157 | $3,969 | $15 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 50 | $3,665 | $65 |
See all 7 services
| Long return visit (40+ min) | 143 | $43,327 | $122 |
| Return visit (30+ min) | 58 | $6,249 | $77 |
| New patient visit (60+ min) | 33 | $4,796 | $145 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 157 | $3,969 | $15 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 50 | $3,665 | $65 |
| Insertion of needle into vein for collection of blood sample | 18 | $796 | $9 |
| Short return visit (20+ min) | 12 | $707 | $59 |
Procedures year by year
| Procedure | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | – | – | 32 | 39 | 56 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
240 Original Medicare patients in 2024. Average age 73 · Under 65 9% · 85 and older 7% · Women 46% · Also on Medicaid 23% · Health risk score 2.95. Above the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 69% · Chronic kidney disease 48% · Heart failure 31% · Coronary heart disease 27% · Diabetes 23% · Atrial fibrillation 21% · Depression 21% · Cancer 16% · COPD 13% · Stroke 9%.
The office billed $4,411,656, Medicare allowed $729,554 and paid $577,575; for 15,480 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 240 | 15,480 | 73 | 2.95 | $4,411,656 | $577,575 |
| 2023 | 219 | 9,659 | 73 | 2.86 | $2,694,612 | $366,217 |
| 2022 | 191 | 2,817 | 72 | 2.66 | $1,034,457 | $128,588 |
| 2021 | 112 | 307 | 73 | 2.42 | $326,281 | $36,649 |
| 2020 | 22 | 39 | 73 | 2.03 | $25,832 | $4,082 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 125 | $31,574 | $122 |
| New patient visit (60+ min) | 54 | $8,008 | $148 |
| Return visit (30+ min) | 44 | $4,953 | $77 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 38 | $2,653 | $68 |
2022: 5 services
| Long return visit (40+ min) | 88 | $30,025 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $8,599 | $91 |
| New patient visit (60+ min) | 57 | $8,502 | $149 |
| Return visit (30+ min) | 29 | $2,940 | $74 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 31 | $2,183 | $68 |
2021: 3 services
| Long return visit (40+ min) | 46 | $17,306 | $130 |
| New patient visit (60+ min) | 55 | $9,018 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $6,556 | $92 |
Medicaid work
$33,463 in 2024
Medicaid paid $33,463 for 235 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 235 | $33,463 |
| 2024 | 235 | 1 | 29 | $33,463 |
| 2023 | 194 | 1 | 27 | $23,800 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 194 | $23,800 |
Drugs they prescribed that Part D paid
$4,228,051
Pharmacies billed $4,228,051 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (28 of 553) in 2024. Above the middle of the specialty; the typical hematology clinician is at 4%.
331 generic and 222 brand-name prescriptions · $4,228,051 in drug cost · 48 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pomalyst | 105 | $2,416,126 | $23,011 |
| Revlimid | 67 | $1,326,094 | $19,792 |
| Lenalidomide | 11 | $158,812 | $14,437 |
| Xarelto | 15 | $23,338 | $1,556 |
| Acyclovir | 74 | $1,720 | $23 |
See all 10 drugs
| Pomalyst | 105 | $2,416,126 | $23,011 |
| Revlimid | 67 | $1,326,094 | $19,792 |
| Lenalidomide | 11 | $158,812 | $14,437 |
| Xarelto | 15 | $23,338 | $1,556 |
| Acyclovir | 74 | $1,720 | $23 |
| Ondansetron | 15 | $1,045 | $70 |
| Dexamethasone | 24 | $342 | $14 |
| Gabapentin | 16 | $290 | $18 |
| Hydromorphone | 12 | $147 | $12 |
| Sulfamethoxazole-Trimethoprim | 34 | $109 | $3 |
Year by year
| 2024 | 553 | 74 | 5% (28) | 40% | $4,228,051 |
| 2023 | 511 | 98 | 6% (31) | None | $3,061,716 |
| 2022 | 587 | 80 | 6% (33) | None | $2,646,934 |
| 2021 | 198 | 34 | None | 25% | $591,499 |
| 2020 | 29 | None | 0% (0) | None | $48,517 |
| 2019 | 25 | None | 0% (0) | None | $3,284 |
| 2016 | 12 | None | None | None | $2,493 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Pomalyst | 53 | $1,256,933 | $23,716 |
| Revlimid | 60 | $1,187,903 | $19,798 |
| Lenalidomide | 33 | $476,172 | $14,429 |
| Xarelto | 29 | $31,330 | $1,080 |
| Entecavir | 14 | $4,918 | $351 |
| Acyclovir | 62 | $2,285 | $37 |
| Oxycodone | 12 | $1,296 | $108 |
| Ondansetron | 22 | $393 | $18 |
| Sulfamethoxazole-Trimethoprim | 26 | $214 | $8 |
| Gabapentin | 20 | $196 | $10 |
| Dexamethasone | 19 | $148 | $8 |
2022: 14 drugs
| Revlimid | 74 | $1,330,528 | $17,980 |
| Pomalyst | 45 | $950,065 | $21,113 |
| Venclexta | 11 | $148,760 | $13,524 |
| Eliquis | 28 | $22,430 | $801 |
| Atovaquone | 18 | $14,652 | $814 |
| Xarelto | 14 | $13,281 | $949 |
| Entecavir | 16 | $5,319 | $332 |
| Acyclovir | 102 | $2,143 | $21 |
| Dexamethasone | 30 | $818 | $27 |
| Ondansetron | 17 | $397 | $23 |
| Oxycodone | 20 | $368 | $18 |
| Prochlorperazine Maleate | 11 | $235 | $21 |
| Sulfamethoxazole-Trimethoprim | 42 | $207 | $5 |
| Gabapentin | 16 | $163 | $10 |
2021: 5 drugs
| Revlimid | 30 | $536,845 | $17,895 |
| Acyclovir | 35 | $962 | $27 |
| Dexamethasone | 12 | $385 | $32 |
| Ondansetron | 11 | $151 | $14 |
| Sulfamethoxazole-Trimethoprim | 19 | $70 | $4 |
2019: 1 drug
| Acyclovir | 12 | $148 | $12 |
Money from drug and device companies
$3,174 in 2025
| 2025 | 3 | 4 | $2,993 | $3,174 |
| 2024 | 2 | 2 | $750 | $773 |
| 2023 | 2 | 8 | $4,125 | $4,292 |
| 2021 | 1 | 1 | $1,728 | $1,728 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $2,993 | 1 payment
|
| Legend Biotech USA | None | $105 | 1 payment
|
| Janssen Biotech | Tecvayli | $76 | 2 payments
|
See all 4 published payments
| Janssen Biotech | Meals · 2025-12-05 | Tecvayli | $19 |
| Janssen Biotech | Meals · 2025-12-05 | Tecvayli | $57 |
| Legend Biotech USA | Meals · 2025-03-29 | None | $105 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-03-24 | None | $2,993 |
See earlier years (2024, 2023, 2021)
2024: $773
| Janssen Biotech | Darzalex | $750 | 1 payment
|
| Genmab U.S. | Epkinly | $23 | 1 payment
|
2023: $4,292
| Janssen Biotech | Darzalex | $4,264 | 7 payments
|
| Pharmacyclics LLC An AbbVie | Epkinly | $28 | 1 payment
|
2021: $1,728
| Genzyme | Sarclisa | $1,728 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After Or Refractory To Anti-Bcma Car-T Therapies · 2022 | Their institution | $354,482 |
| Janssen Research & Development, LLC · A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 2024 | Their institution | $257,403 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2023 | Their institution | $223,120 |
| Janssen Research & Development, LLC · A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 2023 | Their institution | $198,068 |
| Celgene Corporation · A Phase 1, Open-Label, Dose-Finding Study of Bms-986453, Dual Targeting Bcmaxgprc5d Chimeric Antigen Receptor T Cells, in Participants With Relapsed and Or Refractory Multiple Myeloma. · 2025 | Their institution | $160,599 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2024 | Their institution | $158,401 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2024 | Their institution | $137,627 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2025 | Their institution | $128,183 |
| Celgene Corporation · A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma. (Karmma-2) · 2025 | Their institution | $122,301 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2025 | Their institution | $120,579 |
| ABBVIE INC. · A Multicenter Phase 1 Open-Label Dose-Escalation and Expansion Study of Tnb-383b A Bispecific Antibody Targeting Bcma in Subjects With Relapsed Or Refractory Multiple Myeloma · 2025 | Their institution | $104,541 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1, Open-Label, Dose-Finding Study of Bms-986453, Dual Targeting Bcmaxgprc5d Chimeric Antigen Receptor T Cells, in Participants With Relapsed and Or Refractory Multiple Myeloma. · 2025 | Their institution | $100,092 |
| ABBVIE INC. · A Multicenter Phase 1/2 Study of Venetoclax/Daratumumab/Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis · 2024 | Their institution | $77,088 |
| Celgene Corporation · An Efficacy and Safety Study Ofbb2121in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (Karmma-2) · 2024 | Their institution | $65,248 |
| Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After Or Refractory To Anti-Bcma Car-T Therapies · 2024 | Their institution | $64,433 |
| Janssen Research & Development, LLC · A Phase 2, Open-Label, Randomized Study To Evaluate Prophylactic Interventions on Talquetamab-Related Oral Toxicity · 2025 | Their institution | $57,000 |
| Celgene Corporation · Ct Dual Targeting Bcmaxgprc5d Phase I Esc/Exp Fih/Poc/Reg Study · 2024 | Their institution | $40,464 |
| Celgene Corporation · Phii Ide-Cell Ndmm (Bb2121-Mm-004; Karmma-4) - A Phase 1, Open-Label, Multicenter Study To Evaluate the Safety of Bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (Karmma-4) · 2024 | Their institution | $40,046 |
| Janssen Research & Development, LLC · A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 2025 | Their institution | $35,457 |
| Janssen Research & Development, LLC · A Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared With Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2025 | Their institution | $23,708 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2023 | Their institution | $23,092 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2024 | Their institution | $17,902 |
| Janssen Research & Development, LLC · A Multicenter Phase 1/2 Study of Venetoclax / Daratumumab / Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis Patients With Translocation (11;14) (Altitude Study) · 2024 | Their institution | $15,907 |
| Celgene Corporation · Phiib Ide-Cel Multi-Cohort Mm (1l, 2l, 4l+) Karmma-2 (Bb2121-Mm-002) - A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clin · 2023 | Their institution | $14,419 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2022 | Their institution | $12,115 |
| Celgene Corporation · Phii Ide-Cell Ndmm (Bb2121-Mm-004; Karmma-4) - A Phase 1, Open-Label, Multicenter Study To Evaluate the Safety of Bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (Karmma-4) · 2023 | Their institution | $9,274 |
| Genentech, Inc. · Amyloidosis Rwe Consortium · 2023 | Their institution | $3,144 |
| Celgene Corporation · Phii Ide-Cell Ndmm (Bb2121-Mm-004; Karmma-4) - A Phase 1, Open-Label, Multicenter Study To Evaluate the Safety of Bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (Karmma-4) · 2022 | Their institution | $2,692 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417375627
- Licence
- CA A137526California A137526: Current · expires 2026-11-30
- Trained
- Northwestern University Feinberg Medical School, 2014 · 12 years ago
- Group
- UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 400 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2014-04-03
- NPI last updated
- 2021-03-03
- NPI record certified
- 2021-03-03
This is when the NPI record was last certified, not a medical board exam.